Elgan Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2018-05-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.elganpharma.com
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
Phase 2
Not yet recruiting
- Conditions
- Intestinal Malabsorption
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05904626
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Phase 3
Not yet recruiting
- Conditions
- Intestinal Malabsorption
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05670951
Safety and Efficacy Study in Infant With SBS
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT02865122
- Locations
- 🇺🇸
Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Children's Mercy Hospital, Kansas City, Missouri, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Oral Formulation of Insulin for Preterm Infants
Phase 2
Terminated
- Conditions
- Premature Birth of Newborn
- Interventions
- Biological: Oral Formulation of InsulinBiological: Placebo
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Elgan Pharma Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01093638
- Locations
- 🇮🇱
NICU, Laniado Hospital, Netanya, Israel
© Copyright 2025. All Rights Reserved by MedPath